Daily Archives: May 1, 2023

Individuals with chronic conditions have flocked to social media as a source of information, connection, and support. Online social groups are particularly salient for individuals with isolating or stigmatized conditions such as inflammatory bowel dise… Continue reading →

Overlap syndromes (OS) describe the simultaneous presentation of more than one immune-mediated liver disease in a singular patient, and present unique challenges both in diagnosis and treatment. Here we report a case of primary sclerosing cholangitis (… Continue reading →

Obesity among patients with inflammatory bowel disease (IBD) is increasing with prevalence of 15-40%. Studies have shown that obesity may have poor prognostic implications on IBD treatment and outcomes. There is lack of data focused on the management o… Continue reading →

Extraintestinal Manifestations (EIMs) of Inflammatory Bowel Diseases (IBD) are a frequent feature of disease, occurring in 25-40% of patients with IBD. While associations with IBD type, gender, and age at diagnosis are known, less is known about the as… Continue reading →

Crohn’s perianal fistulas (CPFs) are a common complication in patients with Crohn’s disease. Stem cell therapies are under investigation for the treatment of CPF; however, understanding amongst healthcare professionals (HCPs) is unknown and their educa… Continue reading →

Pentosan polysulfate is used for symptomatic management of interstitial cystitis. At one institution we incidentally noted six patients who were on this agent and had a diagnosis of inflammatory bowel disease (IBD). Three of these patients stopped the … Continue reading →

Biosimilars are biologic products similar in safety and efficacy to the originator product. Tumor necrosis factor-alpha inhibitors (anti-TNFs) are used in the treatment of inflammatory bowel diseases (IBD). There are limited studies evaluating the long… Continue reading →

Crohn’s disease (CD) has been known to cause transmural inflammation of the gastrointestinal wall with manifestations including ulcers, abscesses, and fistula. Peptic ulcer disease (PUD) is most commonly caused by Non-Steroid Anti-Inflammatory Drugs (N… Continue reading →

Perianal fistulas occur in ∼30-40% of patients associated with high morbidity and an impaired quality of life. The management of perianal fistulizing CD is a major clinical challenge, where its underlying etiology of is poorly understood. Continue reading →

Given the increase in prevalence of Inflammatory Bowel Disease (IBD) worldwide and the increase in general population life expectancy, it is expected to for IBD to be more prevalent disorder among elderly patients. However, the mortality and outcomes o… Continue reading →